173 related articles for article (PubMed ID: 37350966)
1. Incorporating lesion-to-lesion heterogeneity into early oncology decision making.
Kumar R; Qi T; Cao Y; Topp B
Front Immunol; 2023; 14():1173546. PubMed ID: 37350966
[TBL] [Abstract][Full Text] [Related]
2. RECISTv1.1 progression in oncology: Shades of gray.
Topp B; Snyder A; Wolchok J
Cancer Cell; 2023 Jun; 41(6):1003-1005. PubMed ID: 37172579
[TBL] [Abstract][Full Text] [Related]
3. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.
Chen DT; Chan W; Thompson ZJ; Thapa R; Beg AA; Saltos AN; Chiappori AA; Gray JE; Haura EB; Rose TA; Creelan B
PLoS One; 2021; 16(7):e0252041. PubMed ID: 34197475
[TBL] [Abstract][Full Text] [Related]
4. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment.
Morse B; Jeong D; Ihnat G; Silva AC
Abdom Radiol (NY); 2019 Feb; 44(2):766-774. PubMed ID: 30196362
[TBL] [Abstract][Full Text] [Related]
5. A multistate model for early decision-making in oncology.
Beyer U; Dejardin D; Meller M; Rufibach K; Burger HU
Biom J; 2020 May; 62(3):550-567. PubMed ID: 31310368
[TBL] [Abstract][Full Text] [Related]
6. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
[TBL] [Abstract][Full Text] [Related]
8. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Mushti SL; Mulkey F; Tang S; Singh H; Lemery SJ; Goldberg KB; Sridhara R; Keegan P; Kluetz PG; Pazdur R; Theoret MR; Beaver JA
Curr Oncol Rep; 2020 Aug; 22(11):116. PubMed ID: 32851542
[TBL] [Abstract][Full Text] [Related]
9. Resisting RECIST-Uniformity Versus Clinical Validity.
Wilson MK; Friedlander ML; Lheureux S; Small W; Poveda A; Pujade-Lauraine E; Karakasis K; Bacon M; Bowering V; Chawla T; Oza AM
Int J Gynecol Cancer; 2017 Oct; 27(8):1619-1627. PubMed ID: 28692635
[TBL] [Abstract][Full Text] [Related]
10. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
[TBL] [Abstract][Full Text] [Related]
11. Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response.
Kumar R; Thiagarajan K; Jagannathan L; Liu L; Mayawala K; de Alwis D; Topp B
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):684-695. PubMed ID: 33938166
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
Chelliah V; Lazarou G; Bhatnagar S; Gibbs JP; Nijsen M; Ray A; Stoll B; Thompson RA; Gulati A; Soukharev S; Yamada A; Weddell J; Sayama H; Oishi M; Wittemer-Rump S; Patel C; Niederalt C; Burghaus R; Scheerans C; Lippert J; Kabilan S; Kareva I; Belousova N; Rolfe A; Zutshi A; Chenel M; Venezia F; Fouliard S; Oberwittler H; Scholer-Dahirel A; Lelievre H; Bottino D; Collins SC; Nguyen HQ; Wang H; Yoneyama T; Zhu AZX; van der Graaf PH; Kierzek AM
Clin Pharmacol Ther; 2021 Mar; 109(3):605-618. PubMed ID: 32686076
[TBL] [Abstract][Full Text] [Related]
13. Opportunities for Quantitative Translational Modeling in Oncology.
Yates JWT; Byrne H; Chapman SC; Chen T; Cucurull-Sanchez L; Delgado-SanMartin J; Di Veroli G; Dovedi SJ; Dunlop C; Jena R; Jodrell D; Martin E; Mercier F; Ramos-Montoya A; Struemper H; Vicini P
Clin Pharmacol Ther; 2020 Sep; 108(3):447-457. PubMed ID: 32569424
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor-Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy.
Gong C; Ruiz-Martinez A; Kimko H; Popel AS
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359653
[TBL] [Abstract][Full Text] [Related]
16. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
[TBL] [Abstract][Full Text] [Related]
17. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
18. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
Tazdait M; Mezquita L; Lahmar J; Ferrara R; Bidault F; Ammari S; Balleyguier C; Planchard D; Gazzah A; Soria JC; Marabelle A; Besse B; Caramella C
Eur J Cancer; 2018 Jan; 88():38-47. PubMed ID: 29182990
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis.
Park HJ; Kim KW; Pyo J; Suh CH; Yoon S; Hatabu H; Nishino M
Radiology; 2020 Oct; 297(1):87-96. PubMed ID: 32749204
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
